NCT06660602 Perioperative Cerebral Function Assessment for Cardiac Surgery
| NCT ID | NCT06660602 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China National Center for Cardiovascular Diseases |
| Condition | Cardiac Surgery |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,845 participants |
| Start Date | 2025-02-08 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,845 participants in total. It began in 2025-02-08 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Perioperative neurological complications in cardiovascular surgical procedures are associated with a significant risk of mortality and disability. This study is aimed at identifying the specific risk factors associated with these neurological complications during the perioperation and developing a comprehensive predictive model designed to enhance clinical decision-making and improve patient safety. The research is divided into three key phases: preoperative, intraoperative, and postoperative, each involving targeted evaluations and continuous monitoring to provide a thorough assessment of patient risk and outcomes.
Eligibility Criteria
Inclusion criteria: 1. Age 18-80 years; 2. Patients undergoing cardiovascular surgical procedures; 3. Able to understand and comply with the clinical trial protocol requirements, and willing to sign the informed consent form. Exclusion Criteria: 1. Inability to tolerate required diagnostic procedures, including neck CT angiography (CTA), head CT perfusion (CTP), or electroencephalography (EEG), due to underlying physical limitations or medical contraindications; 2. Severe renal insufficiency, characterized by a creatinine clearance of less than 30 mL/min (using the Cockcroft-Gault formula), serum creatinine levels exceeding twice the upper limit of normal, or any other form of clinically significant renal impairment; 3. Severe hepatic dysfunction, defined by ALT or AST levels greater than three times the upper limit of normal, or the presence of hepatic conditions such as acute or chronic hepatitis, cirrhosis, or other significant liver disorders; 4. Comorbid conditions that may compromise study participation or pose substantial risk to the patient, including, but not limited to, alcohol or substance abuse, malignancies, and severe diseases affecting the liver, kidneys, lungs, endocrine system (e.g., uncontrolled diabetes or thyroid disorders), or hematopoietic system; 5. Inability to cooperate with study procedures, whether due to cognitive, psychological, or physical factors that would impede compliance with protocol requirements; 6. Other conditions deemed unsuitable by the investigator, including any medical or non-medical factors that, in the investigator's assessment, may preclude safe or effective participation in the study.
Contact & Investigator
Li Shujuan, MD
STUDY DIRECTOR
Chinese Academy of Medical Sciences, Fuwai Hospital
Frequently Asked Questions
Who can join the NCT06660602 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cardiac Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06660602 currently recruiting?
Yes, NCT06660602 is actively recruiting participants. Contact the research team at fengyao_dr@sina.com for enrollment information.
Where is the NCT06660602 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06660602 clinical trial?
NCT06660602 is sponsored by China National Center for Cardiovascular Diseases. The principal investigator is Li Shujuan, MD at Chinese Academy of Medical Sciences, Fuwai Hospital. The trial plans to enroll 1,845 participants.